Skip to main content
SpringerLink
Log in

Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene

  • Original Papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

In a pharmacokinetic study on 18 healthy male volunteers the bioavailability and elimination kinetics of furosemide-retard and the combination furosemide-retard/triamterene were investigated and compared with the non-retarded form and another retard form of furosemide. The relative bioavailability of t h e non-retarded form of furosemide was distinctly reduced by the retardation in the substances investigated. It varied between 42–66% in the plasma a n d between 37–73% in the urine. In the combination with triamterene the serum concentration time curve of furosemide was only slightly modified but the renal excretion of furosemide was more influenced (36% for furosemide-retard a n d 25% for furosemide-retard/triamterene). In comparison, the values for the renal excretion of triamterene and OH-TA sulfate were distinctly greater than those obtained after administration of triamterene alone. A renewed increase of the plasma concentration and renal excretion of furosemide were observed between 9 and 10.5 h after administration of furosemideretard/ triamterene. This observation suggests that a further absorption of furosemide occurs as a consequence of the delayed release from distal parts of the small intestine or from the large intestine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beermann B. (1982): Clin. Pharmacol. Ther.,32, 584–591. Kinetics and dynamics of furosemide and slowacting furosemide.

    CAS  PubMed  Google Scholar 

  2. Brodie R.R., Chasseaud L.F., Taylor T., Walmsley L.M. (1979): Journal of Chromatography,164, 527–533. Determination of the diuretic triamterene in plasma and urine of humans by high-performance liquid chromatography.

    Article  CAS  PubMed  Google Scholar 

  3. Buchborn E., Anastasakis S. (1961): Klin. Wschr., 42/22, Angriffspunkt u. Wirkungsmechanismus von Furosemid am distalen Nephron des Menschen.

  4. Burckhardt H., Graul E.H., Pfab R., Schuster O., Loew, D. (1984): Therapie der Herzinsuffizienz mit der Kombination Furosemid retard/Triamteren. Fortschr. Med.27/25, 735–739.

    Google Scholar 

  5. Chennavasin P., Johnson R.A., Brater D.C. (1981): J. Pharmacok. and Biopharmaceut.,9/5, 623–633, Variability in derived parameters of furosemide pharmacokinetics.

    Article  Google Scholar 

  6. Dettli L., Spring P. (1960): Z. ges. exp. Mes.,134, 310. Vergleichende pharmakologische Prüfung eines neuen Saliduretikums (Cyclopenthiazid) am gesunden Menschen.

    Article  Google Scholar 

  7. Dettli L., Spring P. (1965): Arzneim. Forsch.,15, 1162–1168. Pharmakologisch-klinische Prüfung neuer Diuretika. 2. Mitteilung: Furosemid.

    Google Scholar 

  8. Ebihara A., Tawara K., Oka T. (1983): Arzneim. Forsch.,33 (I), 163–166. Pharmacodynamic and phar macokinetic study of a slow-release formulation of furosemide in man.

    CAS  Google Scholar 

  9. Gundert-Remy U., von Kenne D., Weber E., Geissler H.E., Grebian B., Mutschier E. (1979): Eur. J. Clin. Pharmacol.,16, 39–44. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man.

    Article  CAS  PubMed  Google Scholar 

  10. Hasegawa J. (1982): J. Pharmacok. and Biopharmaceut.,10. Pharmacokinetics of triamterene and its metabolite in man.

  11. Heidland A., Klütsch K., Suzuki F. (1974): Arzneim. Forsch.,14, 713–716. Nierenhämodynamic, Wasser- und Elektrolytausscheidung nach 4-Chlor-N-(2-furylmethyl)-5-sulfamoyl-anthranilsäure.

    Google Scholar 

  12. Heinzel G. (1982): in: Bozler G., van Rossum. Pharmacokinetics during drug development: Data analysis and evaluation techniques. G. Fischer, Stuttgart-New York, 207–208. Salient Points of various programs TOPFIT.

    Google Scholar 

  13. Holzgreve H. (1971): Der Internist,12, 337–345. Klinische Pharmakologie der Diuretika.

    PubMed  Google Scholar 

  14. Kleinfelder H. (1963): Dtsch. med. Wschr.,88, 1695–1702. Experimentelle Untersuchungen und klinische Erfahrungnen mit einem neuen Diuretikum.

    CAS  PubMed  Google Scholar 

  15. Knauf H., Wais U., Albiez G., Lübcke R. (1976): Therapiewoche,26, 5384–5387. Kaliumsparer: “Einseitige Diuretika, aber ideale Kombinationspartner”.

    CAS  Google Scholar 

  16. Knauf H., Kraft H., Leilich G., Mutschier E., Schäfe M., Völger K.-D, Vollmer G., Wais U. (1980): Therapiewoche,30/42, 6831–6847. Untersuchungen zum verbesserten therapeutischen Einsatz kaliumsparender Diuretika.

    Google Scholar 

  17. Knauf H., Mutschier E. (1980). Schwerpunktmedizin,3, 42–45. Zur Pharmakokinetik der Diuretika.

    Google Scholar 

  18. Loew D., Ritter W., Dycka J. (1977): Eur. J. Clin. Pharmacol.,12, 341–344. Comparison of t h e pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (Muzolimine).

    Article  CAS  PubMed  Google Scholar 

  19. Loew D., Barkow D., Schuster O., Knoell H.E. (1984): Eur. J. Clin. Pharmacol.,26, 191–195. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.

    Article  CAS  PubMed  Google Scholar 

  20. Meng K. (1969): Klin. Wschr.,47, 668–672. Mikropunktionsuntersuchungen über die Wirkung von Diuretika in der Henle’schen Schleife.

    Article  CAS  PubMed  Google Scholar 

  21. Meng K. (1970): Dtsch. med. Wschr.,95, 2089–2094. Zum renalen Wirkungsmechanismus der Diuretika.

    CAS  PubMed  Google Scholar 

  22. Meng K., Loew D. (1974): Georg Thieme Verlag Stuttgart, Diuretika-Chemie, Pharmakologie, Therapie.

    Google Scholar 

  23. Meng K., Loew D., Stoepel K., Hoffmeister F. (1977): Current Med. Res. Opin.,4, 555–563. Pharmacology of BAY g 2821, a long acting, high ceiling diuretic.

    CAS  Google Scholar 

  24. Merkel W., Bormann D., Mania D., Muschaweck R., Hropot M. (1976): Eur. J. Med. Chem.,11, 399–406. Piretanide (HOE 118), a new high ceiling salidiuretic.

    CAS  Google Scholar 

  25. Müller P., Schaub F. (1964): Klin. Wschr.,42, 958–965. Experimentelle und klinische Untersuchungen mit Etacrynsäure, einem chemisch neuartigen Diuretikum.

    Article  Google Scholar 

  26. Pruitt A.W., Winkel J. S., Dayton P. (1977): Clin. Pharmacol. Ther.,21, 610. Variations in the fate of triamterene.

    CAS  PubMed  Google Scholar 

  27. Rupp W. (1980): Arch. int. Pharmacodyn. Ther.,245/119, 119/129. Some aspects of the clinical pharmacology of furosemide.

    Google Scholar 

  28. Saruta T., Kato E. (1980): Arzneim. Forsch.,30(II)/10, 1807. The diuretic effect of piretanide in man.

    Google Scholar 

  29. Suzuki F., Klütsch K., Heidland A. (1964): Klin. Wschr.,42/12. Stop-flow-Untersuchungen zum Wirkungsmechanismus von Furosemid.

  30. Sved S., Sertie J.A.A., McGilveray I.J. (1979): J. of Chromatogr.,162, 474–479. Rapid assay for triamterene in plasma.

    Article  CAS  Google Scholar 

  31. Schmidt P., Loew D., Dýcka J., Kposa H., Balcke P., Zazgornik J., Deutsch E. (1978): Eur. J. Clin. Pharmacol.,14, 399–403. Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency.

    Article  CAS  PubMed  Google Scholar 

  32. Schmidt P., Schäfer-Körting M., Haubenstock A., Loew D., Mutschier E. (1984): Inn. Med.,11/1, 41–46. Zur Pharmakodynamik und Pharmakokinetik von Furosemid retard/Triamteren bei Patienten mit nephrotischen Ödemen.

    Google Scholar 

  33. Vorburger C. (1971): Internist,12, 345–351. Diuretika bei eingeschränkter Nierenfunktion.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PAZ, Frankfurt/M., F.R.G.

    O. Schuster

  2. Loew, Kuhloweg, 37-39, Iserlohn, F.R.G.

    D. Loew

  3. Battelle-Institut e.V., Frankfurt/M., F.R.G.

    H. E. Knoell

Authors
  1. O. Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Loew
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. E. Knoell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schuster, O., Loew, D. & Knoell, H.E. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene. European Journal of Drug Metabolism and Pharmacokinetics 10, 127–132 (1985). https://doi.org/10.1007/BF03189706

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189706

Key-words

Search

Navigation